Nurix Shares Plunge 35% After Sanofi Terminates Oral STAT6 Degrader SAR448272, While BeOne Medicines Wins FDA Priority Review for BRUKINSA in Frontline Mantle Cell Lymphoma

Nurix Therapeutics shares tumbled roughly 34-38% in after-hours and premarket trading after Sanofi notified the company it was discontinuing the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degrader being developed under a 2019 collaboration agreement, and terminating the program entirely. SAR448272 had been licensed by Sanofi in 2025 when it exercised an option to extend the collaboration to two programs targeting transcription factors for autoimmune and inflammatory diseases, one of which was STAT6. The abrupt end to the program blindsided investors, though Nurix said the decision does not alter its cash runway guidance: the company held $1.1 billion in cash, cash equivalents and marketable securities as of August 31, 2026, sufficient to fund operations into the second half of 2029. Nurix also said it retains eligibility for milestone payments and royalties from other licensed programs under the broader Sanofi collaboration.

Separately, BeOne Medicines received a positive regulatory development when the FDA accepted and granted Priority Review to a supplemental New Drug Application for BRUKINSA (zanubrutinib) in combination with rituximab as a first-line treatment for adult patients with mantle cell lymphoma. The application is backed by data from the pivotal Phase 3 MANGROVE trial, the first Phase 3 study to demonstrate that a BTK inhibitor-based, chemotherapy-free regimen could improve progression-free survival against standard bendamustine plus rituximab chemoimmunotherapy in previously untreated MCL patients.

The week also saw a broad wave of abstract disclosures ahead of the 68th American Society of Hematology Annual Meeting, scheduled for December 12-15, 2026, in New Orleans. Companies including ADC Therapeutics, Geron, Sumitomo Pharma America, Beam Therapeutics, Moderna, Agios, Syndax, and more than a dozen others announced presentations covering hematological malignancies, sickle cell disease, and CAR T-cell therapy programs.